Semnur Pharmaceuticals has closed its business combination with Denali Capital Acquisition Corp, creating a publicly traded entity that will continue to operate as Semnur Pharmaceuticals, Inc. The company’s common stock and warrants are expected to trade on the OTC markets under the symbols SMNR and SMNRW. Scilex Holding Company retains approximately 87.5% ownership of Semnur following the deal, positioning the pain-focused parent with both a late-stage development asset in sciatica and a separate public currency to fund it.
The move raises a strategic question in a tight biotech capital market: can a majority-owned, OTC-listed spinout secure sufficient resources to run a second Phase 3 program and prepare for commercialization while insulating the parent’s balance sheet from development risk? For Scilex, which already markets non-opioid analgesics, ring-fencing Semnur could be a pragmatic way to finance a potentially high-impact procedure-based therapy without diluting its commercial portfolio. For Semnur, the de-SPAC path may be less about valuation optics and more about accessing public capital pools and transactional optionality in a market still cautious on unprofitable growth stories.
The clinical and commercial stakes are clear. Semnur’s lead candidate SP-102 (a dexamethasone sodium phosphate viscous gel) is designed for epidural administration to treat lumbosacral radicular pain, where current practice relies on generic corticosteroids delivered with variable formulation, particulate risk profiles, and inconsistent dwell time. With Fast Track status and one Phase 3 completed, the planned second Phase 3 will need to convincingly demonstrate durable pain reduction, functional improvement, reduced repeat procedures, and a clean safety profile versus standard epidural steroids. If those endpoints land, the value proposition extends beyond non-opioid positioning to procedural efficiency and predictable outcomes—key levers for spine and pain clinics under margin pressure.
Market access will be the decisive battleground. Payers accustomed to pennies-per-milligram generic steroids will demand evidence that a premium, buy-and-bill gel reduces downstream costs: fewer injections, lower opioid rescue use, delayed surgery, and fewer imaging or advanced device interventions. Coding and reimbursement mechanics will matter as much as efficacy—securing permanent HCPCS coding, clarifying site-of-care policies, and aligning distribution between specialty pharmacy and office-administered channels will determine cash flow and clinic adoption. Medical Affairs will need to anchor the narrative with pragmatic RWE in real practice settings, KOL-driven procedural guidance, and health economic analyses tailored to Medicare and large commercial plans. Guideline inclusion in pain, spine, and anesthesiology societies will shape utilization management and prior authorization criteria.
This transaction also fits a broader 2025 pattern: parent companies using SPAC or micro-cap public vehicles to finance late-stage assets while maintaining operational control, particularly in areas where payer evidence and procedural logistics create longer runways to revenue. Non-opioid pain remains investable, but capital is flowing to programs that can translate clinical differentiation into reimbursement advantage. Competitors ranging from generic steroid suppliers to device makers will watch whether a proprietary epidural formulation can reset standards of care, or whether cost containment limits uptake to narrowly defined subgroups.
The next twelve months will tell whether Semnur can turn an OTC listing into a credible financing bridge for Phase 3 and pre-launch work, and whether it can generate the outcomes data payers and proceduralists need. The strategic test is simple: can a first-in-class epidural gel command premium economics in a commoditized procedure—and if so, who follows with combination approaches, bundled payments, or co-promotions that reshape the interventional pain market?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
